Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer — The Smoke Clears

Publisher Website
Google Scholar
Abstract
Lung cancer has been the most common cancer in the world since 1985 and is today the leading cause of cancer-related death. In 2002, there were 1.35 million new cases and 1.18 million related deaths worldwide.1 Non–small-cell lung cancer, the most common form, accounts for 80 to 85 percent of cases. Given the size of the problem, the benefit of adjuvant chemotherapy for non–small-cell lung cancer, reported by Winton et al. in this issue of the Journal, has tremendous implications.2 Complete surgical resection is the best hope for cure in patients with operable non–small-cell lung cancer, yet the five-year overall . . .